Ryman Healthcare Reports Doubling of EBITDA and Positive Cash Flow
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Source: Yahoo Finance
- Strong Financial Performance: Ryman Healthcare achieved positive free cash flow of $188 million for the first time, with operating EBITDA doubling, indicating significant improvements in financial management and boosting investor confidence.
- Significant Cost Savings: The company realized $57 million in annualized cost savings since FY24, exceeding expectations, which enhances profitability and provides funding for future investments.
- High Occupancy Rates: New care centers reached 90% occupancy, surpassing expectations, indicating strong market demand that will help increase overall revenue and market share.
- Optimized Debt Management: Net debt was reduced by $94 million to $1.57 billion, with the average cost of debt decreasing to 5.9%, which will lower financial expenses and enhance the company's financial flexibility.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RYM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RYM
About RYM
RYTHM, Inc., formerly Agrify Corporation, is a provider of branded innovative solutions for the cannabis and hemp industries. The Company’s portfolio of brands includes RYTHM, incredibles, Dogwalkers, Beboe, Senorita THC Margaritas, & Shine, Doctor Solomon’s and Good Green in thousands of physical locations and online channels. The Company’s portfolio of consumer-packaged goods brands includes Senorita brand which offers consumers hemp-derived tetrahydrocannabinol (THC) beverages that mirror well-known cocktails like a margarita in four flavors, including classic Lime JalapeNo Margarita, Mango Margarita, Paloma and Ranch Water. Senorita offers a low-sugar, low-calorie alternative to alcoholic beverages and is available at retailers, including Total Wine, ABC Fine Wine & Spirits, and Binny’s in 11 U.S. states and Canada. Its comprehensive extraction product line includes hydrocarbon, alcohol, solventless, post-processing, and lab equipment.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Ryman Healthcare Reports Doubling of EBITDA and Positive Cash Flow
- Strong Financial Performance: Ryman Healthcare achieved positive free cash flow of $188 million for the first time, with operating EBITDA doubling, indicating significant improvements in financial management and boosting investor confidence.
- Significant Cost Savings: The company realized $57 million in annualized cost savings since FY24, exceeding expectations, which enhances profitability and provides funding for future investments.
- High Occupancy Rates: New care centers reached 90% occupancy, surpassing expectations, indicating strong market demand that will help increase overall revenue and market share.
- Optimized Debt Management: Net debt was reduced by $94 million to $1.57 billion, with the average cost of debt decreasing to 5.9%, which will lower financial expenses and enhance the company's financial flexibility.
See More
Green Thumb's DEA Registration: A Historic Move
- Industry Transformation Opportunity: The DEA's rescheduling of marijuana to Schedule III on April 23, 2026, signifies a shift in perception, categorizing it as having 'moderate to low potential for physical and psychological dependence,' laying the groundwork for the normalization of the medical cannabis industry.
- Strategic Move by Green Thumb: On May 4, 2026, Green Thumb Industries submitted applications to register its state-licensed medical cannabis operations, with CEO Ben Kovler stating that this step will shape the future of medical cannabis in America.
- Investor Confidence Boost: Kovler noted during the quarterly conference call that the DEA registration is expected to attract a significant influx of institutional investors, which could drive Green Thumb's stock price higher and reinforce its position as a leading multistate cannabis operator.
- Research Collaboration Potential: The rescheduling of cannabis may lead to research partnerships with biotech and pharmaceutical companies, enhancing industry development and strengthening Green Thumb's competitive edge in the market.
See More
RYTHM Partners with Navy Pier as Official THC Beverage Brand
- Partnership Announcement: RYTHM, Inc. has established a multi-year partnership with Navy Pier, becoming the official THC beverage partner at a venue that attracts over 8 million visitors annually, significantly enhancing brand visibility and market penetration.
- Product Launch: Starting May 22, RYTHM will introduce its full lineup of THC beverages, including 5mg hemp-derived THC cans, at the Navy Pier Beer Garden, catering to consumer demand for innovative drinks and driving potential sales growth.
- Market Expansion: This partnership marks RYTHM's ongoing expansion into major U.S. entertainment venues, following its historic sponsorship at Chicago's United Center, further solidifying its leadership position in the THC beverage market.
- Cultural Impact: Navy Pier's Chief of Advancement noted that RYTHM's presence will inject new energy into summer programming, supporting public initiatives and enhancing visitor experiences, showcasing the brand's deep integration with this cultural landmark.
See More
Green Thumb Industries Faces Challenges but Analysts Remain Bullish
- Stock Price Decline: As of April 21, Green Thumb Industries' shares have fallen 10% year-to-date, primarily due to slow progress in reforming federal marijuana restrictions in the U.S., which has dampened investor confidence and affected market performance.
- Analyst Optimism: Despite challenges, analysts maintain an average price target of $18.50 per share for Green Thumb, over 100% above the current price, reflecting market expectations for future marijuana law reforms and recognition of the company's potential.
- Profitability Improvement: Green Thumb has been profitable since 2019, operating 113 retail stores and 20 manufacturing facilities; although revenue grew only 3.3% last year, the newly introduced flat-fee licensing model is expected to significantly enhance future profitability.
- Change in Licensing Model: The company announced it will pay a flat $70 million in licensing fees annually, increasing only with the Consumer Price Index, which is expected to help boost incremental earnings and drive further profit growth.
See More
Analysts Bullish on Green Thumb's Future Growth
- Analyst Price Targets: Analysts have set an average price target of $18.50 for Green Thumb Industries, which is over 100% higher than its current trading price, indicating strong market optimism for its future growth potential.
- Licensing Fee Change: On April 1, Green Thumb announced a shift from revenue-based royalties to a fixed annual licensing fee of $70 million, which is expected to significantly enhance the company's profitability moving forward.
- Profitability Boost: Although revenue grew only 3.3% last year, the flat-fee licensing structure will likely allow most incremental revenue to flow directly to profits, further driving earnings growth in upcoming reports.
- Market Environment Challenges: Despite facing challenges from slow progress on federal marijuana reform in the U.S., analysts remain bullish on Green Thumb's performance, suggesting a clear path for potential stock price doubling in the future.
See More
Rythm and Green Thumb Amend Licensing Agreement for Long-Term Revenue
- Agreement Revision: Rythm amended its trademark and recipe licensing agreement with Green Thumb, allowing the latter to continue using Rythm's brand portfolio, including incredibles and Beboe, ensuring sustained market competitiveness.
- Fixed Annual Fee: Under the new terms, effective April 1, 2026, Green Thumb will pay Rythm a fixed annual cash fee of $70 million, with annual increases tied to inflation at twice the Consumer Price Index (CPI), providing Rythm with a stable long-term revenue stream.
- Stock Price Surge: Rythm's shares surged nearly 45% on Wednesday, marking the largest intraday gain of 2026 and breaching the 100-day moving average for the first time since December 18, 2025, indicating strong market confidence in its future growth.
- Market Sentiment Shift: Retail sentiment for RYM shifted from 'neutral' to 'extremely bullish', reflecting positive reactions to the new agreement, particularly regarding the anticipated boost in Rythm's gross margins from the royalty fees.
See More
Ryman Healthcare Reports Doubling of EBITDA and Positive Cash Flow
- Strong Financial Performance: Ryman Healthcare achieved positive free cash flow of $188 million for the first time, with operating EBITDA doubling, indicating significant improvements in financial management and boosting investor confidence.
- Significant Cost Savings: The company realized $57 million in annualized cost savings since FY24, exceeding expectations, which enhances profitability and provides funding for future investments.
- High Occupancy Rates: New care centers reached 90% occupancy, surpassing expectations, indicating strong market demand that will help increase overall revenue and market share.
- Optimized Debt Management: Net debt was reduced by $94 million to $1.57 billion, with the average cost of debt decreasing to 5.9%, which will lower financial expenses and enhance the company's financial flexibility.
See More
Green Thumb's DEA Registration: A Historic Move
- Industry Transformation Opportunity: The DEA's rescheduling of marijuana to Schedule III on April 23, 2026, signifies a shift in perception, categorizing it as having 'moderate to low potential for physical and psychological dependence,' laying the groundwork for the normalization of the medical cannabis industry.
- Strategic Move by Green Thumb: On May 4, 2026, Green Thumb Industries submitted applications to register its state-licensed medical cannabis operations, with CEO Ben Kovler stating that this step will shape the future of medical cannabis in America.
- Investor Confidence Boost: Kovler noted during the quarterly conference call that the DEA registration is expected to attract a significant influx of institutional investors, which could drive Green Thumb's stock price higher and reinforce its position as a leading multistate cannabis operator.
- Research Collaboration Potential: The rescheduling of cannabis may lead to research partnerships with biotech and pharmaceutical companies, enhancing industry development and strengthening Green Thumb's competitive edge in the market.
See More
RYTHM Partners with Navy Pier as Official THC Beverage Brand
- Partnership Announcement: RYTHM, Inc. has established a multi-year partnership with Navy Pier, becoming the official THC beverage partner at a venue that attracts over 8 million visitors annually, significantly enhancing brand visibility and market penetration.
- Product Launch: Starting May 22, RYTHM will introduce its full lineup of THC beverages, including 5mg hemp-derived THC cans, at the Navy Pier Beer Garden, catering to consumer demand for innovative drinks and driving potential sales growth.
- Market Expansion: This partnership marks RYTHM's ongoing expansion into major U.S. entertainment venues, following its historic sponsorship at Chicago's United Center, further solidifying its leadership position in the THC beverage market.
- Cultural Impact: Navy Pier's Chief of Advancement noted that RYTHM's presence will inject new energy into summer programming, supporting public initiatives and enhancing visitor experiences, showcasing the brand's deep integration with this cultural landmark.
See More
Green Thumb Industries Faces Challenges but Analysts Remain Bullish
- Stock Price Decline: As of April 21, Green Thumb Industries' shares have fallen 10% year-to-date, primarily due to slow progress in reforming federal marijuana restrictions in the U.S., which has dampened investor confidence and affected market performance.
- Analyst Optimism: Despite challenges, analysts maintain an average price target of $18.50 per share for Green Thumb, over 100% above the current price, reflecting market expectations for future marijuana law reforms and recognition of the company's potential.
- Profitability Improvement: Green Thumb has been profitable since 2019, operating 113 retail stores and 20 manufacturing facilities; although revenue grew only 3.3% last year, the newly introduced flat-fee licensing model is expected to significantly enhance future profitability.
- Change in Licensing Model: The company announced it will pay a flat $70 million in licensing fees annually, increasing only with the Consumer Price Index, which is expected to help boost incremental earnings and drive further profit growth.
See More
Analysts Bullish on Green Thumb's Future Growth
- Analyst Price Targets: Analysts have set an average price target of $18.50 for Green Thumb Industries, which is over 100% higher than its current trading price, indicating strong market optimism for its future growth potential.
- Licensing Fee Change: On April 1, Green Thumb announced a shift from revenue-based royalties to a fixed annual licensing fee of $70 million, which is expected to significantly enhance the company's profitability moving forward.
- Profitability Boost: Although revenue grew only 3.3% last year, the flat-fee licensing structure will likely allow most incremental revenue to flow directly to profits, further driving earnings growth in upcoming reports.
- Market Environment Challenges: Despite facing challenges from slow progress on federal marijuana reform in the U.S., analysts remain bullish on Green Thumb's performance, suggesting a clear path for potential stock price doubling in the future.
See More
Rythm and Green Thumb Amend Licensing Agreement for Long-Term Revenue
- Agreement Revision: Rythm amended its trademark and recipe licensing agreement with Green Thumb, allowing the latter to continue using Rythm's brand portfolio, including incredibles and Beboe, ensuring sustained market competitiveness.
- Fixed Annual Fee: Under the new terms, effective April 1, 2026, Green Thumb will pay Rythm a fixed annual cash fee of $70 million, with annual increases tied to inflation at twice the Consumer Price Index (CPI), providing Rythm with a stable long-term revenue stream.
- Stock Price Surge: Rythm's shares surged nearly 45% on Wednesday, marking the largest intraday gain of 2026 and breaching the 100-day moving average for the first time since December 18, 2025, indicating strong market confidence in its future growth.
- Market Sentiment Shift: Retail sentiment for RYM shifted from 'neutral' to 'extremely bullish', reflecting positive reactions to the new agreement, particularly regarding the anticipated boost in Rythm's gross margins from the royalty fees.
See More
